Britain's GSK released new data from early-stage studies, citing that its antibody-based Covid-19 therapy with US partner Vir is effective against all mutations of the new Omicron coronavirus variant, Reuters reports.

The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement.